Renovorx reports first quarter 2025 financial results and business highlights

Mountain view, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a life sciences company developing innovative targeted oncology therapies and commercializing renovocath®, a novel, fda-cleared drug-delivery device, today announced its financial results and business updates for the first quarter ended march 31, 2025. renovocath powers renovorx's patented trans-arterial micro-perfusion (tamp™) therapy platform. “i am pleased to report a milestone event for reno.
RNXT Ratings Summary
RNXT Quant Ranking